Outsourcing

Grant Playter is the Assistant Editor for 

Articles

The trends shaping the growth of the biologics outsourcing industry demand attention.

The Logistics of Outsourcing Biologics

The technology is designed to enable patients to self-inject biologic-based therapies at home instead of a hospital setting. 

Elektrofi Establishes Contract Manufacturing Agreement with Thermo Fisher Scientific

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.

CellVax and Theragent Form Manufacturing Pact for Novel Cancer Immunotherapy Drug Candidate

Under two new agreements, Societal CDMO will offer analytical, technical transfer, formulation, manufacturing, and packaging services for novel therapeutics.

Societal CDMO Signs Multiple CDMO Service Agreements

Meg Rivers is the former senior editor for 

Experts divulge where the industry is outsourcing most frequently, when companies should outsource more, and when performing tasks in-house might be best.

Deciding Where to Outsource in Biopharma Development and Manufacturing

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.

Lonza, IBF Collaborate to Support Development and Manufacturing of Biologics and Small Molecules

Industry experts share their top outsourcing tips from both the perspective of companies offering outsourcing services as well as for companies looking to outsource. 


What Outsourcing Partners Wish You Knew

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

Outsourcing partners are ready to fill the market need for greater cell therapies capacities.

Scaling Up Cell Therapies Capacity

The booming cell therapy market has created a need for capacity that outsourcing partners are ready to fill.

Scaling Up Capacity for Cell Therapies

Jennifer Markarian is manufacturing editor of BioPharm International.

BioPharm International spoke with Colleen Floreck, vice president, Global Marketing and Strategy, Catalent Cell and Gene Therapy about the specific requirements and challenges for expanding production of viral vectors. 

Contract Manufacturing, Biopharmaceutical Production